This company has been acquired
Satsuma Pharmaceuticals Management
Management criteria checks 2/4
Satsuma Pharmaceuticals' CEO is John Kollins, appointed in Jul 2016, he has a tenure of 6.92 years. His total yearly compensation is $1.91M , comprised of 27.8% salary and 72.2% bonuses, including company stock and options. He directly owns 0.94% of the company’s shares, worth $341.95K. The average tenure of the management team and the board of directors is 5.9 years and 5.8 years respectively.
Key information
John Kollins
Chief executive officer
US$1.9m
Total compensation
| CEO salary percentage | 27.8% |
| CEO tenure | 6.9yrs |
| CEO ownership | 0.9% |
| Management average tenure | 5.9yrs |
| Board average tenure | 5.8yrs |
Recent management updates
Recent updates
Can Satsuma Pharmaceuticals (NASDAQ:STSA) Afford To Invest In Growth?
Feb 15
Will Satsuma Pharmaceuticals (NASDAQ:STSA) Spend Its Cash Wisely?
Sep 02Here's Why We're Watching Satsuma Pharmaceuticals' (NASDAQ:STSA) Cash Burn Situation
May 13Satsuma Pharmaceuticals: Sizing Up This One Trick Pony
Nov 07Satsuma shares surge on data from early-stage STS101 trial
Jun 16Do Institutions Own Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA) Shares?
Jan 26CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2023 | n/a | n/a | -US$65m |
| Dec 31 2022 | US$2m | US$530k | -US$70m |
| Sep 30 2022 | n/a | n/a | -US$62m |
| Jun 30 2022 | n/a | n/a | -US$61m |
| Mar 31 2022 | n/a | n/a | -US$56m |
| Dec 31 2021 | US$830k | US$500k | -US$51m |
| Sep 30 2021 | n/a | n/a | -US$48m |
| Jun 30 2021 | n/a | n/a | -US$47m |
| Mar 31 2021 | n/a | n/a | -US$46m |
| Dec 31 2020 | US$4m | US$456k | -US$48m |
| Sep 30 2020 | n/a | n/a | -US$46m |
| Jun 30 2020 | n/a | n/a | -US$42m |
| Mar 31 2020 | n/a | n/a | -US$37m |
| Dec 31 2019 | US$1m | US$391k | -US$28m |
| Sep 30 2019 | n/a | n/a | -US$20m |
| Jun 30 2019 | n/a | n/a | -US$13m |
| Mar 31 2019 | n/a | n/a | -US$8m |
| Dec 31 2018 | US$568k | US$362k | -US$7m |
Compensation vs Market: John's total compensation ($USD1.91M) is above average for companies of similar size in the US market ($USD740.57K).
Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.
CEO
John Kollins (60 yo)
6.9yrs
Tenure
US$1,909,812
Compensation
Mr. John A. Kollins, MBA, has been Director, President and Chief Executive Officer of Satsuma Pharmaceuticals, Inc since July 2016. He served as Chief Business Officer and Senior Vice President of Transcep...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 6.9yrs | US$1.91m | 0.94% $ 342.0k | |
| Chief Financial Officer | 4.4yrs | US$936.85k | 0.042% $ 15.3k | |
| VP & Head of Operations | 6.4yrs | no data | no data | |
| Senior VP & Head of Chemistry | 5.9yrs | no data | no data | |
| VP & Head of Regulatory Affairs | 5.1yrs | no data | no data |
5.9yrs
Average Tenure
58yo
Average Age
Experienced Management: STSA's management team is seasoned and experienced (5.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 6.9yrs | US$1.91m | 0.94% $ 342.0k | |
| Independent Director | 2.9yrs | US$132.08k | 0% $ 0 | |
| Independent Director | 5.8yrs | US$131.58k | 0% $ 0 | |
| Independent Chairman of the Board | 6.5yrs | US$160.08k | 0% $ 0 | |
| Independent Director | 6.5yrs | US$120.58k | 0% $ 0 | |
| Independent Director | 1.7yrs | US$124.58k | 0% $ 0 | |
| Independent Director | 7yrs | US$124.08k | 0% $ 0 | |
| Independent Director | 4.1yrs | US$132.08k | 0% $ 0 | |
| Independent Director | 5.7yrs | US$126.08k | 0% $ 0 |
5.8yrs
Average Tenure
59yo
Average Age
Experienced Board: STSA's board of directors are considered experienced (5.8 years average tenure).